Immunex Enbrel
Executive Summary
Sales of rheumatoid arthritis therapy Enbrel (etanercept) totaled $59.7 mil. during first full quarter on the market, Immunex reports. The initial sell-in of Enbrel was $12.7 mil. during the fourth quarter of 1998. Immunex majority owner American Home Products cited the performance of Enbrel as one factor contributing to growth of the Wyeth-Ayerst pharmaceutical business during the quarter